SPODUMENE
Phase 2 Unknown
21 enrolled
ATG-010(Selinexor) in Combination With Chemotherapy in RRMM
Phase 2 Unknown
50 enrolled
MoTD
Phase 2 Unknown
400 enrolled
Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma
Phase 2 Unknown
27 enrolled
A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma
Phase 2 Unknown
60 enrolled
LENDER
Phase 2 Unknown
70 enrolled
PVd Versus Vd in NDMM Patients With RI
Phase 2 Unknown
79 enrolled
Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma
Phase 2 Unknown
199 enrolled
KMM2002
Phase 2 Unknown
33 enrolled
Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM)
Phase 2 Unknown
30 enrolled
KMM1911
Phase 2 Unknown
58 enrolled
BEAM
Phase 2 Unknown
100 enrolled
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
Phase 2 Unknown
51 enrolled
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor
Phase 2 Unknown
108 enrolled
ICE
Phase 2 Unknown
21 enrolled
IFM2018-01
Phase 2 Unknown
45 enrolled
Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT
Phase 2 Unknown
80 enrolled
Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma
Phase 2 Unknown
30 enrolled
DART4MM
Phase 2 Unknown
50 enrolled
B Cell Maturation Antigen(BMCA)-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma
Phase 2 Unknown
30 enrolled
ProT4
Phase 2 Unknown
114 enrolled
PREDATOR
Phase 2 Unknown
274 enrolled
DARIA
Phase 2 Unknown
50 enrolled
MM-POM-2018
Phase 2 Unknown
18 enrolled
CARFI
Phase 2 Unknown
200 enrolled
Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM
Phase 2 Unknown
25 enrolled
Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib
Phase 2 Unknown
100 enrolled
REBUILD
Phase 2 Unknown
57 enrolled
Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma.
Phase 2 Unknown
94 enrolled
METDEXA-MM
Phase 2 Unknown
28 enrolled
Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies
Phase 2 Unknown
24 enrolled
SUTRICA
Phase 2 Unknown
300 enrolled
Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment
Phase 2 Unknown
30 enrolled
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers
Phase 2 Unknown
10 enrolled
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Phase 2 Unknown
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
Phase 2 Unknown
52 enrolled
Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia
Phase 2 Unknown
30 enrolled
Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Phase 2 Unknown
35 enrolled
A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b
Phase 2 Unknown
17 enrolled
Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma
Phase 2 Unknown
60 enrolled
Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation
Phase 2 Unknown
80 enrolled
Busulfan and Melphalan Conditioning in Multiple Myeloma
Phase 2 Unknown
105 enrolled
High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma
Phase 2 Unknown
100 enrolled
KMM-97
Phase 2 Unknown
78 enrolled
Bortezomib
Phase 2 Unknown
20 enrolled
Bortezomib and High-dose Melphalan at Myeloma Relapse
Phase 2 Unknown
50 enrolled
Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma
Phase 2 Unknown
80 enrolled
Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders
Phase 2 Unknown
50 enrolled
AlloTreo
Phase 2 Unknown
175 enrolled
Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma
Phase 2 Unknown
43 enrolled